Skip to Content

HER2-Low Treatment – The Future of this Important Biomarker

Paolo Tarantino, from the Dana-Farber Cancer Institute, highlights the transformative potential of novel antibody-drug conjugates in treating HER2-positive and HER2-low breast cancer. Through recent trials, Tarantino challenges traditional assumptions about HER2 expression and demonstrates promising outcomes for HER2-low tumours.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top